PURPOSE: We explored the clinical usefulness of serum carbonic anhydrase 9 as a potential biomarker for conventional renal cell cancer. MATERIALS AND METHODS: This study included 91 patients with conventional renal cell cancer and 32 healthy individuals. Enzyme linked immunosorbent assay was used to measure the carbonic anhydrase 9 level. A followup (median 38 months) was performed to track early recurrence after surgery for patients with localized disease. Recurrence-free survival curves were calculated by the Kaplan-Meier method and compared using the log rank test. RESULTS: The mean serum carbonic anhydrase 9 level in patients with metastatic conventional renal cell cancer (216.68 +/- 67.02 pg/ml) or localized conventional renal cell cancer (91.65 +/- 13.29 pg/ml) was significantly higher than in healthy individuals (14.59 +/- 6.22 pg/ml, p <0.001 and p = 0.001, respectively). The mean serum carbonic anhydrase 9 level in patients with metastatic conventional renal cell cancer was significantly higher than in those with localized disease (p = 0.004). Of patients with localized disease those with recurrence had a significantly higher serum carbonic anhydrase 9 than those without recurrence (p = 0.001). On univariate analysis serum carbonic anhydrase 9, tumor stage, tumor grade and tumor size were associated with recurrence. The recurrence-free survival curve indicates that patients with a high serum carbonic anhydrase 9 level had a significantly higher recurrence rate than those with a low serum carbonic anhydrase 9 (p = 0.001). CONCLUSIONS: Our data suggest that serum carbonic anhydrase 9 is increased as the tumor progression occurs. A high carbonic anhydrase 9 level is associated with postoperative recurrence.
PURPOSE: We explored the clinical usefulness of serum carbonic anhydrase 9 as a potential biomarker for conventional renal cell cancer. MATERIALS AND METHODS: This study included 91 patients with conventional renal cell cancer and 32 healthy individuals. Enzyme linked immunosorbent assay was used to measure the carbonic anhydrase 9 level. A followup (median 38 months) was performed to track early recurrence after surgery for patients with localized disease. Recurrence-free survival curves were calculated by the Kaplan-Meier method and compared using the log rank test. RESULTS: The mean serum carbonic anhydrase 9 level in patients with metastatic conventional renal cell cancer (216.68 +/- 67.02 pg/ml) or localized conventional renal cell cancer (91.65 +/- 13.29 pg/ml) was significantly higher than in healthy individuals (14.59 +/- 6.22 pg/ml, p <0.001 and p = 0.001, respectively). The mean serum carbonic anhydrase 9 level in patients with metastatic conventional renal cell cancer was significantly higher than in those with localized disease (p = 0.004). Of patients with localized disease those with recurrence had a significantly higher serum carbonic anhydrase 9 than those without recurrence (p = 0.001). On univariate analysis serum carbonic anhydrase 9, tumor stage, tumor grade and tumor size were associated with recurrence. The recurrence-free survival curve indicates that patients with a high serum carbonic anhydrase 9 level had a significantly higher recurrence rate than those with a low serum carbonic anhydrase 9 (p = 0.001). CONCLUSIONS: Our data suggest that serum carbonic anhydrase 9 is increased as the tumor progression occurs. A high carbonic anhydrase 9 level is associated with postoperative recurrence.
Authors: Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun Journal: Eur Urol Date: 2011-07-05 Impact factor: 20.096
Authors: Yulian Mytsyk; Victor Dosenko; Yuriy Borys; Askold Kucher; Katarina Gazdikova; Dietrich Busselberg; Martin Caprnda; Peter Kruzliak; Ammad Ahmad Farooqi; Manyuk Lubov Journal: Int Urol Nephrol Date: 2018-03-16 Impact factor: 2.370
Authors: Martina Takacova; Maria Bartosova; Lucia Skvarkova; Miriam Zatovicova; Ivana Vidlickova; Lucia Csaderova; Monika Barathova; Jan Breza; Peter Bujdak; Jaromir Pastorek; Jan Breza; Silvia Pastorekova Journal: Oncol Lett Date: 2012-10-26 Impact factor: 2.967
Authors: M Ilie; N M Mazure; V Hofman; R E Ammadi; C Ortholan; C Bonnetaud; K Havet; N Venissac; B Mograbi; J Mouroux; J Pouysségur; P Hofman Journal: Br J Cancer Date: 2010-05-11 Impact factor: 7.640
Authors: Dina Schütze; Karin Milde-Langosch; Isabell Witzel; Achim Rody; Thomas Karn; Marcus Schmidt; Matthias Choschzick; Fritz Jänicke; Volkmar Müller Journal: J Cancer Res Clin Oncol Date: 2013-01-29 Impact factor: 4.553